Philip An Nguyen, PA
Physician Assistant · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Philip An Nguyen’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G61857 · Current
Licensed to practise in California · since 1987 · expires 2027-10-31 · University of California San Francisco School of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$4,510
Medicare paid this office $4,510 for 79 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 29 | $3,264 | $96 |
| Urinalysis, manual test | 63 | $242 | $3 |
Who their Medicare patients are
79 Original Medicare patients in 2024. Average age 76 · Women 14% · Also on Medicaid 0% · Health risk score 1.02. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Coronary heart disease 47% · Chronic kidney disease 35% · Cancer 33% · Diabetes 32% · Atrial fibrillation 20% · Stroke 14%.
The office billed $24,254, Medicare allowed $5,853 and paid $4,510; for 132 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$44,588
Pharmacies billed $44,588 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (25 of 506) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
460 generic and fewer than 11 brand-name prescriptions · $44,588 in drug cost · 224 antibiotic prescriptions to 139 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 12 | $16,001 | $1,333 |
| Tamsulosin | 106 | $1,441 | $14 |
| Silodosin | 12 | $1,140 | $95 |
| Nitrofurantoin Mono-Macro | 13 | $680 | $52 |
| Ciprofloxacin | 132 | $582 | $4 |
See all 9 drugs
| Mounjaro | 12 | $16,001 | $1,333 |
| Tamsulosin | 106 | $1,441 | $14 |
| Silodosin | 12 | $1,140 | $95 |
| Nitrofurantoin Mono-Macro | 13 | $680 | $52 |
| Ciprofloxacin | 132 | $582 | $4 |
| Hydrocodone-Acetaminophen | 20 | $142 | $7 |
| Cephalexin | 22 | $114 | $5 |
| Amoxicillin-Clavulanate Potass | 12 | $112 | $9 |
| Sulfamethoxazole-Trimethoprim | 33 | $88 | $3 |
Money from drug and device companies
$2,183 in 2025
| 2025 | 18 | 78 | None | $2,183 |
| 2024 | 11 | 24 | None | $744 |
| 2023 | 10 | 19 | None | $586 |
| 2022 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $1,119 | 35 payments
|
| Janssen Biotech | Erleada | $200 | 6 payments
|
| Abbvie | Botox | $131 | 5 payments
|
| Novartis Pharmaceuticals | Pluvicto | $105 | 4 payments
|
| Verity Pharmaceuticals | Tlando | $99 | 5 payments
|
| Accord Healthcare | Camcevi | $90 | 4 payments
|
See all 78 published payments
| Teleflex | Meals · 2025-12-30 | Urolift | $25 |
| Sumitomo Pharma America | Meals · 2025-12-22 | Gemtesa | $8 |
| Sumitomo Pharma America | Meals · 2025-12-19 | Gemtesa | $32 |
| Sumitomo Pharma America | Meals · 2025-12-12 | Gemtesa | $40 |
| Abbvie | Meals · 2025-12-09 | Botox | $26 |
| Sumitomo Pharma America | Meals · 2025-12-03 | Gemtesa | $38 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-24 | None | $29 |
| Procept Biorobotics | Meals · 2025-11-24 | Aquabeam Robotic System | $15 |
| Sumitomo Pharma America | Meals · 2025-11-21 | Gemtesa | $40 |
| Verity Pharmaceuticals | Meals · 2025-11-17 | Tlando | $18 |
| Sumitomo Pharma America | Meals · 2025-11-11 | Gemtesa | $22 |
| Accord Healthcare | Meals · 2025-11-10 | Camcevi | $16 |
| 180 Medical | Meals · 2025-11-05 | None | $22 |
| Sumitomo Pharma America | Meals · 2025-11-02 | Gemtesa | $45 |
| Janssen Biotech | Meals · 2025-10-28 | Erleada | $31 |
| Sumitomo Pharma America | Meals · 2025-10-24 | Gemtesa | $38 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Pluvicto | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-13 | None | $25 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $36 |
| Verity Pharmaceuticals | Meals · 2025-10-07 | Tlando | $24 |
| Accord Healthcare | Meals · 2025-10-01 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-09-25 | Gemtesa | $123 |
| Sumitomo Pharma America | Meals · 2025-09-25 | Gemtesa | $40 |
| Janssen Biotech | Meals · 2025-09-24 | Erleada | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-16 | None | $28 |
| Sumitomo Pharma America | Meals · 2025-09-11 | Gemtesa | $13 |
| Verity Pharmaceuticals | Meals · 2025-09-09 | Tlando | $16 |
| Sumitomo Pharma America | Meals · 2025-09-05 | Gemtesa | $38 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-02 | Nubeqa | $22 |
| Progenics Pharmaceuticals | Meals · 2025-08-26 | Pylarify | $26 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | Pluvicto | $19 |
| Sumitomo Pharma America | Meals · 2025-08-13 | Gemtesa | $38 |
| Verity Pharmaceuticals | Meals · 2025-08-13 | Tlando | $23 |
| Astellas Pharma US | Meals · 2025-08-12 | Xtandi | $25 |
| Abbvie | Meals · 2025-08-06 | Botox | $32 |
| Sumitomo Pharma America | Meals · 2025-07-31 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-07-22 | Gemtesa | $14 |
| Verity Pharmaceuticals | Meals · 2025-07-21 | Tlando | $18 |
| Accord Healthcare | Meals · 2025-07-17 | Camcevi | $26 |
| Progenics Pharmaceuticals | Meals · 2025-07-09 | Pylarify | $21 |
| Sumitomo Pharma America | Meals · 2025-06-29 | Gemtesa | $10 |
| Sumitomo Pharma America | Meals · 2025-06-19 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-06-09 | Gemtesa | $16 |
| Endo USA | Meals · 2025-06-08 | Xiaflex | $29 |
| Novartis Pharmaceuticals | Meals · 2025-06-05 | Pluvicto | $32 |
| Sumitomo Pharma America | Meals · 2025-05-28 | Gemtesa | $39 |
| Abbvie | Meals · 2025-05-21 | Botox | $25 |
| Sumitomo Pharma America | Meals · 2025-05-16 | Gemtesa | $17 |
| Pfizer | Meals · 2025-05-13 | Xtandi | $22 |
| Agiliti Surgical | Meals · 2025-05-13 | Sonablate Hifu | $22 |
| Sumitomo Pharma America | Meals · 2025-05-09 | Gemtesa | $31 |
| Janssen Biotech | Meals · 2025-05-08 | Erleada | $13 |
| Janssen Biotech | Meals · 2025-05-07 | Erleada | $28 |
| Sumitomo Pharma America | Meals · 2025-05-02 | Gemtesa | $41 |
| Janssen Biotech | Meals · 2025-04-26 | Rybrevant | $69 |
| Sumitomo Pharma America | Meals · 2025-04-25 | Gemtesa | $41 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Pluvicto | $34 |
| Abbvie | Meals · 2025-04-18 | Botox | $24 |
| Lantheus Medical Imaging | Meals · 2025-04-14 | None | $15 |
| Accord Healthcare | Meals · 2025-04-03 | Camcevi | $24 |
| Astellas Pharma US | Meals · 2025-03-31 | Xtandi | $21 |
| Sumitomo Pharma America | Meals · 2025-03-26 | Gemtesa | $26 |
| Abbvie | Meals · 2025-03-24 | Botox | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-24 | Nubeqa | $27 |
| Sumitomo Pharma America | Meals · 2025-03-19 | Gemtesa | $42 |
| Janssen Biotech | Meals · 2025-03-18 | Erleada | $25 |
| Telix Pharmaceuticals | Meals · 2025-03-14 | Illuccix | $26 |
| Sumitomo Pharma America | Meals · 2025-03-12 | Gemtesa | $40 |
| Telix Pharmaceuticals | Meals · 2025-03-02 | Illuccix | $20 |
| Sumitomo Pharma America | Education · 2025-02-28 | Gemtesa | $5 |
| Sumitomo Pharma America | Meals · 2025-02-27 | Gemtesa | $26 |
| Sumitomo Pharma America | Meals · 2025-02-14 | Gemtesa | $36 |
| Astellas Pharma US | Meals · 2025-02-11 | Xtandi | $20 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $23 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $18 |
| Sumitomo Pharma America | Meals · 2025-01-29 | Gemtesa | $28 |
| Sumitomo Pharma America | Meals · 2025-01-14 | Gemtesa | $9 |
| Sumitomo Pharma America | Meals · 2025-01-09 | Gemtesa | $37 |
See earlier years (2024, 2023, 2022)
2024: $744
| Sumitomo Pharma America | Gemtesa | $280 | 9 payments
|
| Blue Earth Diagnostics | Posluma | $99 | 3 payments
|
| Astellas Pharma US | None | $89 | 1 payment
|
| Janssen Biotech | Erleada | $86 | 4 payments
|
| Dendreon Pharmaceuticals | Provenge | $32 | 1 payment
|
| ConvaTec | Gentlecath | $32 | 1 payment
|
| Immunitybio | Anktiva | $32 | 1 payment
|
| Olympus America | Itind System | $30 | 1 payment
|
| Endo USA | Xiaflex | $24 | 1 payment
|
| Novartis Pharmaceuticals | Pluvicto | $20 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
2023: $586
| Sumitomo Pharma America | Gemtesa | $139 | 4 payments
|
| Agiliti Surgical | Sonablate | $99 | 1 payment
|
| Janssen Biotech | Erleada | $87 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $63 | 3 payments
|
| Dendreon Pharmaceuticals | Provenge | $48 | 2 payments
|
| Tolmar | Jatenzo | $41 | 2 payments
|
| Ethicon US | Vistaseal | $38 | 1 payment
|
| Myriad Genetic Laboratories | Prolaris | $31 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $21 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $20 | 1 payment
|
2022: $12
| Antares Pharma | Nocdurna | $12 | 1 payment
|
Professional record
- NPI
- 1669182986
- Licence
- CA 61857California G61857: Current · expires 2027-10-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2633 Sherlock Dr, San Jose, CA, 95121
- NPI first listed
- 2022-11-28
- NPI last updated
- 2022-11-28
- NPI record certified
- 2022-11-28
This is when the NPI record was last certified, not a medical board exam.